MRPL3 Prognostic Biomarker Research for Lung Adenocarcinoma

Lan Yin's 2026 research paper validates MRPL3 as a prognostic biomarker and therapeutic target in lung adenocarcinoma. The study integrates gene expression data from TCGA and GEO cohorts to build a lactylation-disulfidptosis gene signature model. Experimental validation includes in vitro and in vivo tests showing MRPL3 knockdown inhibits tumor growth.

Use Cases

• Validate prognostic gene signatures based on lactylation and disulfidptosis pathways described in the research.
• Investigate MRPL3's role in glycolytic-lactate metabolism and immune microenvironment remodeling as outlined in the study.
• Benchmark experimental validation methods for biomarker discovery using the described in vitro and in vivo approaches.

Strengths

• Model validated across TCGA, GEO testing set, and external validation cohorts.
• Includes experimental validation via in vitro and in vivo experiments.

Limitations

• Dataset is a 12.0 KB DOCX document, likely containing research text rather than raw data tables.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

figshare

Collection Method

Research analysis using TCGA and GEO gene expression profiles, followed by experimental validation.

Freshness

Last updated 2026-05-19 05:40:21; freshness should be verified.